Witryna1 gru 2024 · The IMPower-010 trial interrupted the negative trend of adjuvant lung cancer immunotherapy, paving the way to the application of immune-checkpoint inhibition in the resected disease. The ITACA trial definitively established no role for tailored adjuvant chemotherapy in NSCLC, while the Lung Art data questioned the efficacy of … Witryna25 wrz 2024 · The IMpower133 trial evaluated the efficacy and safety of adding atezolizumab or placebo to first-line treatment with carboplatin and etoposide in patients with extensive-stage small-cell lung...
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer …
Witryna9 paź 2024 · Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, … WitrynaImpower-010 scores on an apparently approvable endpoint, but the effect in all-comers is illusory, researchers reckon. Roche’s Tecentriq looks on track to become the first immunotherapy to be approved for the perioperative treatment of non-small cell lung cancer, data from the adjuvant study Impower-010 just unveiled at the virtual iphone repeats the same song
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Witryna9 gru 2024 · The IMpower010 trial reported earlier this year that atezolizumab improved disease-free survival (DFS) compared with best supportive care (BSC) in patients with stage II–IIIA resected non-small cell lung cancer (NSCLC) ( Lancet. 2024;398 (10308):1344–1357 ). Patients were stratified by SP142-determined PD-L1 status. WitrynaOur trial evaluated as exploratory end points how different PD-L1 scoring methods perform to predict the activity of atezolizumab as compared with chemotherapy. Witryna1 lip 2015 · Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung … iphone replacement battery - best buy